NCT03450083View on ClinicalTrials.gov

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

January 1, 2020

Study Completion Date

February 1, 2020

Conditions
Chronic Rhinosinusitis (Diagnosis)Nasal PolypsEosinophilia
Interventions
DRUG

Benralizumab

30mg Benralizumab will be delivered subcutaneously

DRUG

Placebo

Subcutaneous placebo injection

Trial Locations (1)

21224

Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03450083 - Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis | Biotech Hunter | Biotech Hunter